Influence of omalizumab on treatment costs for chronic rhinosinusitis with nasal polyps and asthma: an insurance claims analysis

• Type of Material: Article
• Authors: Lauren T Roland, University of California San Francisco; Sarah Wise, Emory University; Heqiong Wang, Emory University; Christina Mehta, Emory University; John DelGaudio, Emory University; Joshua Levy, Emory University
• Language: English
• Date: 2021-10-01
• Publisher: WILEY
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2021 ARS-AAOA, LLC
• Final Published Version (URL): http://dx.doi.org/10.1002/alr.22904
• Title of Journal or Parent Work: INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY
• Volume: 12
• Issue: 3
• Start Page: 310
• End Page: 312
• Grant/Funding Information: AAOA Foundation.
• Keywords: Life Sciences & Biomedicine; Science & Technology; Otorhinolaryngology

Abstract

Biologics were recently approved for chronic rhinosinusitis with nasal polyps (CRSwNP),1 with promising results regarding symptom improvement. Biologics are expected to be used as long-term medications, due to worsening of symptoms when treatment is stopped.2 Cost-effectiveness analyses for use in CRSwNP suggest that surgical treatment is more cost-effective compared with biologics,3 and biologics have been found to be cost-effective only for severe asthmatics.4,5 CRSwNP patients with comorbid asthma have been shown to have a higher overall cost burden than those with CRSwNP alone.6 Recent work suggests that biologics prescribed for the indication of asthma provide improvement of comorbid CRSwNP symptoms.7 The goal of this study was to describe the costs for patients with CRSwNP and asthma who received biologic medication among a nationally representative insurance claims database.